An Artificial Pancreas for Automated Blood Glucose Control in Patients With Type 1 Diabetes

Abstract

Automated glucose control in patients with Type 1 diabetes is much-coveted by patients, relatives and healthcare professionals. It is the expectation that a system for automated control, also know as an artificial pancreas, will improve glucose control, reduce the risk of diabetes complications and markedly improve patient quality of life. An artificial pancreas consists of portable devices for glucose sensing and insulin delivery which are controlled by an algorithm residing on a computer. The technology is still under development and currently no artificial pancreas is commercially available. This review gives an introduction to recent progress, challenges and future prospects within the field of artificial pancreas research.

Financial & competing interests disclosure

S Schmidt, D Boiroux and A Ranjan are funded by research grants from the Danish Diabetes Academy supported by the Novo Nordisk Foundation. S Schmidt serves on the CGM advisory board of Roche Diagnostics. K N⊘rgaard serves on the insulin pump advisory board of Medtronic and owns shares in Novo Nordisk. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.